| Not Yet Recruiting | At-Home Paracentesis for Women With Cancer-Related Malignant Ascites (Paracentesis) NCT07490626 | University of Utah | N/A |
| Recruiting | Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Hum NCT07397819 | Dong sheng Zhang | Phase 1 / Phase 2 |
| Recruiting | A Phase I Study of SIM0388 in Participants With Malignant Ascites. NCT07007988 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Active Not Recruiting | Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody NCT06432296 | Wuhan YZY Biopharma Co., Ltd. | Phase 3 |
| Recruiting | Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer NCT06016179 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 1 |
| Recruiting | The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF NCT06433869 | Sun Yat-sen University | Phase 2 |
| Unknown | Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases NCT05477927 | Sichuan University | Phase 1 |
| Unknown | A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced b NCT06200376 | West China Hospital | Phase 1 |
| Unknown | PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites NCT05501340 | Second Affiliated Hospital of Soochow University | Phase 1 / Phase 2 |
| Completed | Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody NCT06266091 | Wuhan YZY Biopharma Co., Ltd. | Phase 2 |
| Enrolling By Invitation | Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites NCT05745233 | China Medical University Hospital | N/A |
| Withdrawn | Malignant Ascites Alfapump® Study NCT04076566 | Sequana Medical N.V. | — |
| Completed | Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites NCT04051112 | Sichuan Clover Biopharmaceuticals, Inc. | Phase 1 |
| Unknown | A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Asci NCT03736122 | BioSyngen Pte Ltd | Phase 1 / Phase 2 |
| Completed | A Study of M701 (EpCAM and CD3) in Malignant Ascites NCT04501744 | Wuhan YZY Biopharma Co., Ltd. | Phase 1 |
| Unknown | EUS-Guided Drainage of Refractory Malignant Ascites NCT03550560 | Hospital Universitario Virgen Macarena | — |
| Active Not Recruiting | International Alfapump Cohort Study NCT04326946 | Sequana Medical N.V. | — |
| Completed | Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics NCT04032600 | Charite University, Berlin, Germany | N/A |
| Completed | Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites NCT03200106 | Sequana Medical N.V. | — |
| Unknown | Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant As NCT03230708 | Hui ting Xu，MD | Phase 1 / Phase 2 |
| Unknown | A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites NCT03020979 | The First Affiliated Hospital of Bengbu Medical University | Phase 2 |
| Unknown | Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter. NCT02724683 | Maciej Stukan, MD, PhD | — |
| Unknown | A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites NCT02530398 | Dongfang Hospital Beijing University of Chinese Medicine | Phase 1 |
| Terminated | Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites NCT02496286 | Eastern Regional Medical Center | Phase 1 |
| Completed | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritone NCT02122185 | University of Chicago | Phase 2 |
| Unknown | Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Eff NCT01854866 | Huazhong University of Science and Technology | Phase 2 |
| Completed | ALFApump System Post Marketing Surveillance Registry NCT01532427 | Sequana Medical N.V. | — |
| Completed | Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites NCT01327235 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 2 |
| Terminated | Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion NCT01262612 | Radboud University Medical Center | Phase 2 |
| Completed | Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Ga NCT01200121 | AIO-Studien-gGmbH | Phase 2 |
| Terminated | An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Ple NCT01077063 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Withdrawn | A Study of Bevacizumab to Prevent Malignant Ascites NCT00908219 | Baylor College of Medicine | Phase 2 |
| Completed | CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites NCT00822809 | Neovii Biotech | Phase 3 |
| Completed | Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites NCT00326885 | Neovii Biotech | Phase 2 |
| Completed | Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control NCT00836654 | Neovii Biotech | Phase 2 / Phase 3 |
| Terminated | EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for NCT00028782 | National Cancer Institute (NCI) | N/A |